サイトカイン放出症候群管理の世界市場レポート 2025年

サイトカイン放出症候群管理市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.5％で306億9,000万米ドルに成長します。予測期間における成長の原動力は、診断ツールや治療に対する需要の増加、政府助成金の増加、効果的な治療法に対するニーズの高まり、高齢化、官民両組織によるイニシアチブの拡大などであると予想されます。予測期間の主な動向としては、低侵襲性乳房生検装置の開発、戦略的パートナーシップと提携、在宅抗生物質注入サービス、新規ドラッグデリバリー・システムの出現、感染追跡のための電子カルテの統合などが挙げられます。

標的治療薬の使用の増加は、今後数年間のサイトカイン放出症候群管理市場の成長を促進すると予想されます。標的療法は、腫瘍の開発に関与する分子経路を標的とすることで、がんの成長と拡大を阻止するように特別に設計された治療法です。標的治療薬の増加は、主に健康な細胞への害を最小限に抑えながらがん細胞を正確に標的とする能力に起因しており、従来の治療法と比較して治療効果が向上し、副作用が軽減されます。CRSの管理は、CAR-T細胞療法や免疫チェックポイント阻害剤などの治療の安全性と有効性を高めるため、重篤な炎症反応をコントロールすることによって標的治療を最適化する上で重要な役割を果たしています。例えば、2024年1月、米国遺伝子・細胞治療学会（American Society of Gene and Cell Therapy）は、2023年第4四半期に第III相臨床試験中の遺伝子治療薬の数が10％増加したと報告しました。このため、標的療法の利用拡大がサイトカイン放出症候群管理市場の成長を後押ししています。

サイトカイン放出症候群管理市場の主要企業は、宿主指向性低分子薬などの革新的な治療法の開発に注力しており、感染症やがんと闘う身体の能力を損なうことなく、免疫反応を調節しサイトカインストームの重症度を軽減することを目指しています。宿主指向性低分子医薬品とは、宿主の免疫シグナル伝達経路を標的とするように設計された低分子化合物であり、過剰なサイトカイン産生を抑制し、免疫系の過剰活性化を防ぐことによってCRSの管理に役立ちます。例えば、2025年4月、米国のバイオテクノロジー企業であるCytoAgents Inc.は、CAR-T細胞療法を受けている患者におけるCRSの予防と治療を目的とした宿主指向性低分子薬剤CTO1681の第1b/2a相臨床試験において、最初の用量漸増コホートが成功裏に終了したと発表しました。この治験薬は良好な安全性プロファイルを示し、用量制限毒性もCAR T細胞の有効性を阻害することもありませんでした。現在進行中の試験は、CTO1681の安全性、忍容性、予備的有効性を評価し、推奨される第2相用量を決定するためのものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界サイトカイン放出症候群管理PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のサイトカイン放出症候群管理市場：成長率分析
• 世界のサイトカイン放出症候群管理市場の実績：規模と成長、2019～2024年
• 世界のサイトカイン放出症候群管理市場の予測：規模と成長、2024～2029年、2034年
• 世界サイトカイン放出症候群管理総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のサイトカイン放出症候群管理市場：治療の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• コルチコステロイド
• 静脈内免疫グロブリン（IVIG）
• 標的療法
• 支持療法
• その他の治療の種類
• 世界のサイトカイン放出症候群管理市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• キメラ抗原受容体（CAR）T細胞療法
• 免疫チェックポイント阻害剤
• 造血幹細胞移植（HSCT）
• 自己免疫疾患
• 感染症
• その他の適応症
• 世界のサイトカイン放出症候群管理市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 静脈内（IV）
• 皮下（SC）
• オーラル
• 筋肉内（IM）
• 脊髄内
• その他の投与経路
• 世界のサイトカイン放出症候群管理市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 専門クリニック
• 調査機関
• その他のエンドユーザー
• 世界のサイトカイン放出症候群管理市場：モノクローナル抗体の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• トシリズマブ
• シルツキシマブ
• インフリキシマブ
• リツキシマブ
• その他のモノクローナル抗体
• 世界のサイトカイン放出症候群管理市場：コルチコステロイドの種類別、実績と予測、2019～2024年、2024～2029年、2034年
• デキサメタゾン
• プレドニゾン
• メチルプレドニゾロン
• ヒドロコルチゾン
• その他のコルチコステロイド
• 世界のサイトカイン放出症候群管理市場：静脈内免疫グロブリン（IVIG）の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫グロブリンG（IgG）ベースの静脈内免疫グロブリン
• 免疫グロブリンA（IgA）ベースの静脈内免疫グロブリン
• 免疫グロブリンM（IgM）ベースの静脈内免疫グロブリン
• 多価静脈内免疫グロブリン
• その他の種類の静脈内免疫グロブリン
• 世界のサイトカイン放出症候群管理市場：標的療法の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• ヤヌスキナーゼ（JAK）阻害剤
• インターロイキン-6（IL-6）阻害剤
• 腫瘍壊死因子アルファ（TNF-α）阻害剤
• ブルトン型チロシンキナーゼ（BTK）阻害剤
• その他の標的エージェント
• 世界のサイトカイン放出症候群管理市場：支持療法の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 解熱剤
• 鎮痛薬
• 静脈内輸液と電解質溶液
• 酸素療法
• 血管収縮薬
• 世界のサイトカイン放出症候群管理市場：その他の治療の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 血漿交換療法（治療的血漿交換）
• 抗ヒスタミン薬
• 白血球除去療法
• 実験的治療法
• 栄養サポート

第7章 地域別・国別分析

• 世界のサイトカイン放出症候群管理市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のサイトカイン放出症候群管理市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• サイトカイン放出症候群管理市場：競合情勢
• サイトカイン放出症候群管理市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol Myers Squibb Company
• Novartis AG
• GlaxoSmithKline plc
• Amgen Inc.
• Gilead Sciences Inc.
• Regeneron Pharmaceuticals Inc.
• Genentech Inc.
• Incyte Corporation
• Swedish Orphan Biovitrum AB
• Biocon Limited
• MacroGenics Inc.
• Legend Biotech Corporation
• Bluebird Bio Inc.
• InflaRx N.V.
• Humanigen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• サイトカイン放出症候群管理市場2029：新たな機会を提供する国
• サイトカイン放出症候群管理市場2029：新たな機会を提供するセグメント
• サイトカイン放出症候群管理市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cytokine release syndrome (CRS) management involves medical strategies to control the excessive immune response caused by an overproduction of cytokines, often seen in conditions such as CAR-T cell therapy or certain infections. The management approach includes medications such as corticosteroids and cytokine inhibitors, supportive care, and, in some cases, intensive monitoring to prevent severe complications. Effective management is critical for reducing the risk of severe organ damage and improving patient outcomes.

The primary treatment options for CRS include monoclonal antibodies, corticosteroids, intravenous immunoglobulin (IVIG), targeted therapy, supportive care, and other treatments. Monoclonal antibodies are laboratory-engineered molecules that target specific cytokines or their receptors to regulate immune activity and manage CRS. These antibodies are used for a range of conditions, including chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, hematopoietic stem cell transplantation (HSCT), autoimmune diseases, infections, and others. They can be administered intravenously (IV), subcutaneously (SC), orally, intramuscularly (IM), intrathecally, or by other methods. These treatments are provided through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, specialty clinics, research institutions, and others.

The cytokine release syndrome management market research report is one of a series of new reports from The Business Research Company that provides cytokine release syndrome management market statistics, including cytokine release syndrome management industry global market size, regional shares, competitors with a cytokine release syndrome management market share, cytokine release syndrome management market segments, market trends, and opportunities, and any further data you may need to thrive in the cytokine release syndrome management industry. This cytokine release syndrome management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cytokine release syndrome management market size has grown strongly in recent years. It will grow from $22.32 billion in 2024 to $23.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. Growth during the historic period can be attributed to rising healthcare expenditures, increasing awareness, changing lifestyles, higher disposable incomes, the adoption of personalized medicine approaches, and greater use of targeted therapies.

The cytokine release syndrome management market size is expected to see strong growth in the next few years. It will grow to $30.69 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. Growth in the forecast period is expected to be driven by increased demand for diagnostic tools and treatments, growing government funding, a rising need for effective therapies, an aging population, and expanding initiatives by both public and private organizations. Key trends in the forecast period include the development of minimally invasive breast biopsy devices, strategic partnerships and collaborations, home-based antibiotic infusion services, the emergence of novel drug delivery systems, and the integration of electronic health records for infection tracking.

The increasing use of targeted therapies is expected to drive the growth of the cytokine release syndrome management market in the coming years. Targeted therapies are treatments specifically designed to block the growth and spread of cancer by targeting molecular pathways involved in tumor development. The rise in targeted therapies is mainly attributed to their ability to precisely target cancer cells while minimizing harm to healthy cells, which improves treatment efficacy and reduces side effects compared to traditional therapies. CRS management plays a vital role in optimizing targeted therapies by controlling severe inflammatory responses, thus enhancing the safety and effectiveness of treatments such as CAR-T cell therapy and immune checkpoint inhibitors. For example, in January 2024, the American Society of Gene and Cell Therapy reported that in the fourth quarter of 2023, the number of gene therapies in Phase III clinical trials increased by 10%, marking the first rise of this kind since the third quarter of 2022. Therefore, the growing use of targeted therapies is fueling the growth of the cytokine release syndrome management market.

Major companies in the cytokine release syndrome management market are focusing on developing innovative therapies, such as host-directed small molecule drugs, which aim to modulate the immune response and reduce the severity of cytokine storms without compromising the body's ability to fight infections or cancer. A host-directed small molecule drug is a low molecular weight compound designed to target immune signaling pathways in the host, helping manage CRS by suppressing excessive cytokine production and preventing immune system overactivation. For instance, in April 2025, CytoAgents Inc., a US-based biotechnology company, announced the successful completion of the first dose-escalation cohort in its Phase 1b/2a clinical trial of CTO1681, a host-directed small molecule drug aimed at preventing and treating CRS in patients receiving CAR T-cell therapy. The investigational therapy showed a favorable safety profile, with no dose-limiting toxicities or disruption to CAR T-cell efficacy. The ongoing trial is designed to assess the safety, tolerability, and preliminary efficacy of CTO1681 and determine the recommended Phase 2 dose.

In March 2024, Merck & Co., Inc., a US-based biopharmaceutical company, acquired Harpoon Therapeutics for \$680 million to strengthen its oncology pipeline with innovative T-cell engager therapies. This acquisition integrates Harpoon's T-cell engager technology and lead candidate, MK-6070, currently in a Phase 1/2 trial for advanced cancers, enhancing Merck's immuno-oncology capabilities and expanding its portfolio of next-generation cancer therapies. Harpoon Therapeutics, a clinical-stage biopharmaceutical company, specializes in T-cell engagers for cancer treatment, focusing on its TriTAC-XR platform to reduce CRS and improve treatment efficacy.

Major players in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., and Humanigen Inc.

North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cytokine release syndrome management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cytokine release syndrome management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cytokine release syndrome management market consists of revenues earned by entities by providing services such as diagnostic testing, immunosuppressive therapy, supportive care, clinical trial services, and post-treatment monitoring to manage and treat patients affected by CRS. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine release syndrome management market also includes sales of tocilizumab (actemra), siltuximab (sylvant), dexamethasone, ruxolitinib (jakafi), and ivig (intravenous immunoglobulin). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cytokine Release Syndrome Management Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cytokine release syndrome management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cytokine release syndrome management ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cytokine release syndrome management market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Monoclonal Antibodies; Corticosteroids; Intravenous Immunoglobulin (IVIG); Targeted Therapy; Supportive Care; Other Treatment Types
• 2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy; Immune Checkpoint Inhibitors; Hematopoietic Stem Cell Transplantation (HSCT); Autoimmune Diseases; Infections; Other Indications
• 3) By Route Of Administration: Intravenous (IV); Subcutaneous (SC); Oral; Intramuscular (IM); Intrathecal; Other Routes Of Administration
• 4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics; Research Institutions; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Tocilizumab; Siltuximab; Infliximab; Rituximab; Other Monoclonal Antibodies
• 2) By Corticosteroids: Dexamethasone; Prednisone; Methylprednisolone; Hydrocortisone; Other Corticosteroids
• 3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin; Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin; Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin; Polyvalent Intravenous Immunoglobulin; Other Types of Intravenous Immunoglobulin
• 4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors; Interleukin-6 (IL-6) Inhibitors; Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors; Bruton's Tyrosine Kinase (BTK) Inhibitors; Other Targeted Agents
• 5) By Supportive Care: Antipyretic Medications; Analgesic Medications; Intravenous Fluids And Electrolyte Solutions; Oxygen Therapy; Vasopressor Agents
• 6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange); Antihistamine Medications; Leukapheresis; Experimental Therapies; Nutritional Support
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cytokine Release Syndrome Management Market Characteristics

3. Cytokine Release Syndrome Management Market Trends And Strategies

4. Cytokine Release Syndrome Management Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cytokine Release Syndrome Management Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cytokine Release Syndrome Management PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cytokine Release Syndrome Management Market Growth Rate Analysis
• 5.4. Global Cytokine Release Syndrome Management Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cytokine Release Syndrome Management Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cytokine Release Syndrome Management Total Addressable Market (TAM)

6. Cytokine Release Syndrome Management Market Segmentation

• 6.1. Global Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Corticosteroids
• Intravenous Immunoglobulin (IVIG)
• Targeted Therapy
• Supportive Care
• Other Treatment Types
• 6.2. Global Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chimeric Antigen Receptor (CAR) T-Cell Therapy
• Immune Checkpoint Inhibitors
• Hematopoietic Stem Cell Transplantation (HSCT)
• Autoimmune Diseases
• Infections
• Other Indications
• 6.3. Global Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV)
• Subcutaneous (SC)
• Oral
• Intramuscular (IM)
• Intrathecal
• Other Routes Of Administration
• 6.4. Global Cytokine Release Syndrome Management Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Research Institutions
• Other End Users
• 6.5. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tocilizumab
• Siltuximab
• Infliximab
• Rituximab
• Other Monoclonal Antibodies
• 6.6. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dexamethasone
• Prednisone
• Methylprednisolone
• Hydrocortisone
• Other Corticosteroids
• 6.7. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Intravenous Immunoglobulin (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin
• Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin
• Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin
• Polyvalent Intravenous Immunoglobulin
• Other Types of Intravenous Immunoglobulin
• 6.8. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Janus Kinase (JAK) Inhibitors
• Interleukin-6 (IL-6) Inhibitors
• Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors
• Bruton's Tyrosine Kinase (BTK) Inhibitors
• Other Targeted Agents
• 6.9. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antipyretic Medications
• Analgesic Medications
• Intravenous Fluids And Electrolyte Solutions
• Oxygen Therapy
• Vasopressor Agents
• 6.10. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasmapheresis (Therapeutic Plasma Exchange)
• Antihistamine Medications
• Leukapheresis
• Experimental Therapies
• Nutritional Support

7. Cytokine Release Syndrome Management Market Regional And Country Analysis

• 7.1. Global Cytokine Release Syndrome Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cytokine Release Syndrome Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cytokine Release Syndrome Management Market

• 8.1. Asia-Pacific Cytokine Release Syndrome Management Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cytokine Release Syndrome Management Market

• 9.1. China Cytokine Release Syndrome Management Market Overview
• 9.2. China Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cytokine Release Syndrome Management Market

• 10.1. India Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cytokine Release Syndrome Management Market

• 11.1. Japan Cytokine Release Syndrome Management Market Overview
• 11.2. Japan Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cytokine Release Syndrome Management Market

• 12.1. Australia Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cytokine Release Syndrome Management Market

• 13.1. Indonesia Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cytokine Release Syndrome Management Market

• 14.1. South Korea Cytokine Release Syndrome Management Market Overview
• 14.2. South Korea Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cytokine Release Syndrome Management Market

• 15.1. Western Europe Cytokine Release Syndrome Management Market Overview
• 15.2. Western Europe Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cytokine Release Syndrome Management Market

• 16.1. UK Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cytokine Release Syndrome Management Market

• 17.1. Germany Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cytokine Release Syndrome Management Market

• 18.1. France Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cytokine Release Syndrome Management Market

• 19.1. Italy Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cytokine Release Syndrome Management Market

• 20.1. Spain Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cytokine Release Syndrome Management Market

• 21.1. Eastern Europe Cytokine Release Syndrome Management Market Overview
• 21.2. Eastern Europe Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cytokine Release Syndrome Management Market

• 22.1. Russia Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cytokine Release Syndrome Management Market

• 23.1. North America Cytokine Release Syndrome Management Market Overview
• 23.2. North America Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cytokine Release Syndrome Management Market

• 24.1. USA Cytokine Release Syndrome Management Market Overview
• 24.2. USA Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cytokine Release Syndrome Management Market

• 25.1. Canada Cytokine Release Syndrome Management Market Overview
• 25.2. Canada Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cytokine Release Syndrome Management Market

• 26.1. South America Cytokine Release Syndrome Management Market Overview
• 26.2. South America Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cytokine Release Syndrome Management Market

• 27.1. Brazil Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cytokine Release Syndrome Management Market

• 28.1. Middle East Cytokine Release Syndrome Management Market Overview
• 28.2. Middle East Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cytokine Release Syndrome Management Market

• 29.1. Africa Cytokine Release Syndrome Management Market Overview
• 29.2. Africa Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cytokine Release Syndrome Management Market Competitive Landscape And Company Profiles

• 30.1. Cytokine Release Syndrome Management Market Competitive Landscape
• 30.2. Cytokine Release Syndrome Management Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Cytokine Release Syndrome Management Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb Company
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Amgen Inc.
• 31.5. Gilead Sciences Inc.
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Genentech Inc.
• 31.8. Incyte Corporation
• 31.9. Swedish Orphan Biovitrum AB
• 31.10. Biocon Limited
• 31.11. MacroGenics Inc.
• 31.12. Legend Biotech Corporation
• 31.13. Bluebird Bio Inc.
• 31.14. InflaRx N.V.
• 31.15. Humanigen Inc.

32. Global Cytokine Release Syndrome Management Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cytokine Release Syndrome Management Market

34. Recent Developments In The Cytokine Release Syndrome Management Market

35. Cytokine Release Syndrome Management Market High Potential Countries, Segments and Strategies

• 35.1 Cytokine Release Syndrome Management Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cytokine Release Syndrome Management Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cytokine Release Syndrome Management Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer